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Abstract
The Breastfeeding, Antiretrovirals, and Nutrition Study evaluated the effect of daily consumption of lipid-based nutrient
supplements (LNS) by 2121 lactating, HIV-infected mothers on the growth of their exclusively breast-fed, HIV-uninfected
infants from 0 to 24wk. The study had a 23 3 factorial design.Malawianmothers with CD4+$250 cells/mm3, hemoglobin
$70 g/L, and BMI$17 kg/m2 were randomized within 36 h of delivery to receive either no LNS or 140 g/d of LNS to meet
lactation energy and protein needs, and mother-infant pairs were assigned to maternal antiretroviral drugs (ARV), infant
ARV, or no ARV. Sex-stratified, longitudinal, random effects models were used to estimate the effect of the 6 study arms
on infant weight, length, and BMI. Logistic regression models were used to calculate the odds of growth faltering [decline
in weight-for-age Z-score (WAZ) or length-for-age Z-score (LAZ) .0.67] using the control arm as the reference. Although
some differences between study arms emergedwith increasing infant age in boys, therewere no consistent effects of the
maternal supplement across the 3 growth outcomes in longitudinal models. At the ageswhere differenceswere observed,
the effects on weight and BMI were quite small (#200 g and#0.4 kg/m2) and unlikely to be of clinical importance. Overall,
21 and 34% of infants faltered in WAZ and LAZ, respectively. Maternal supplementation did not reduce the odds of infant
weight or length faltering from 0 to 24 wk in any arm. These results indicate that blanket supplementation of HIV-infected
lactating women may have little impact on infant growth. J. Nutr. 142: 1350–1356, 2012.
Introduction
The improved availability of antiretroviral therapy for prevention
of mother-to-child transmission has increased the number of HIV-
exposed, uninfected infants (1,2).Maintaining the health and growth
of HIV-exposed infants is an important public health aim, linked to
at least 2 of the United NationsMillennium Development Goals (3).
HIV-exposed infants living in resource-poor settings face
many challenges compared with their unexposed peers. If they
are fully weaned early or not breastfed, then they are at risk of
growth faltering and early death due to increased incidence of
infectious diseases and inadequate dietary intake (4–6). If they
are breastfed in the absence of antiretroviral drugs (ARV)13,
infants of HIV-infected mothers are at risk of contracting HIV
through breast milk, especially when complementary foods are
added to the infant diet during the first 6 mo of life (7–9). To
address these issues in settings where the national authorities
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have decided to support breastfeeding and ARV use, the WHO
currently recommends that HIV-infected mothers exclusively
breastfeed their infants for 6 mo, introduce complementary
foods thereafter, and continue breastfeeding until 12 mo (10).
Breastfeeding should stop only when a safe, nutritionally
adequate diet without breast milk is available.
Although exclusive breastfeeding is essential for the growth
and health of HIV-exposed infants in low-resource settings,
lactating HIV-infected women may become nutritionally de-
pleted and suffer excess weight loss because of the increased
metabolic demands of both breastfeeding and HIV infection
(11–14). It is unclear how seriously these demands affect their
own health. Two studies found that weight loss in HIV-infected
mothers during lactation led to higher mortality among these
women (15,16), whereas 2 other studies found no association of
breastfeeding with mortality (17,18).
In addition to possible impacts on their own health, unmet
nutritional needs of HIV-infected mothers may also affect their
children through poor-quality breast milk and reduced capacity
for child care [e.g., through the effect of anemia on maternal
responsiveness (19,20)]. Lactating HIV-infected mothers in
resource-poor settings have lower levels of several micronutri-
ents than uninfected mothers (21). The energy and micro-
nutrient content of breast milk is dependent on maternal dietary
intake and stores, and some nutrients in breast milk can be
increased with supplementation (22,23). The effects of maternal
supplementation during pregnancy and lactation on infant
growth are mixed (23–29), but it appears that improvements
in maternal weight status and infant growth are more likely to
occur in thinner mothers (23,24). We expected to find that HIV-
infected mothers in a country with regular food insecurity would
fall into this category.
The Breastfeeding, Antiretrovirals, and Nutrition (BAN)
study was a randomized-controlled intervention trial designed to
test the effects of daily consumption of lipid-based nutrient
supplements (LNS) by lactating HIV-infected mothers on their
weight status and the provision of ARV to mothers or infants
during the period of exclusive breastfeeding on MTCT. Mothers
in the study who received LNS lost less weight during 6 mo of
exclusive breastfeeding than mothers who did not receive LNS
regardless of ARV assignment (30). Here, we assess the effect of
BAN study interventions on infant weight, length, and BMI
during the period of exclusive breastfeeding, from 0 to 24 wk.
Participants and Methods
Study population. The methods used in the BAN study have been
described in detail elsewhere (31). Briefly, HIV-1–infected, pregnant
women were recruited at antenatal clinics in Lilongwe, Malawi.
Eligibility criteria included: $14 y if married or $18 y if not married,
CD4+ count $250 cells/mm3 (CD4+ count $200 cells/mm3 before July
2006), hemoglobin $70 g/L, normal liver function tests, no previous
ARV use, and no serious complications of pregnancy (such as hemor-
rhage or eclampsia). After delivery, mother-infant pairs who met the
following secondary eligibility criteria were randomized: birth weight
$2 kg, enrollment within 36 h of delivery, maternal acceptance of 7-d
perinatal ARV regimen for herself and her infant, and no maternal
condition that would preclude the use of a study drug (such as hypotension
or severe infection). Data were collected on randomized mother-infant
pairs from April 2004 to January 2010. Infants who were found to be
HIV-positive by PCR methods within the first 2 wk of life were un-
enrolled from the study, together with their mothers, and referred for
ARV treatment.
Ethical approval of the study protocol was obtained from theMalawi
National Health Science Research Committee and the Institutional
Review Boards at the University of North Carolina at Chapel Hill and
the U.S. CDC.
Study interventions. The study had a 2 3 3 factorial design. Mothers
were randomly assigned to receive LNS or no LNS, and mother-infant
pairs were randomly assigned to maternal ARV, infant ARV, or no ARV.
Following delivery and eligibility screening, mother-infant pairs were
randomized, using a permuted block method, to 1 of 6 study arms:
maternal LNS/maternal ARV (mLNS-mARV), maternal LNS/infant
ARV (mLNS-iARV), maternal LNS (mLNS), maternal ARV (mARV),
infant ARV (iARV), or control (C) (31). Mother and infant interventions
began within 36 h of delivery and continued to 28 wk postpartum or
until breastfeeding cessation, if earlier. Participants were followed until
48 wk. The nutrition intervention was given to one-half of the mothers in
the form of 140 g/d of LNS, which contained 3120 kJ of energy and
100% of the recommended dietary allowance of micronutrients for
lactating women (Table 1). The daily quantity of LNS was selected to
offset the energy and protein costs of lactation (32) and was intended to
be consumed in addition to regular foods. LNS were produced by
Nutriset and contained peanut butter, vegetable oil, dried skimmed milk
powder, dry whey, sugar, and micronutrients. The maternal ARV
intervention consisted of a 3-drug, highly-active regimen, and the infant
regimen included daily oral nevirapine. Details about the ARV regimens
are described elsewhere (8). In addition, all mothers and infants were
given an intrapartum dose of nevirapine and postpartum ARV for 7 d.
All BAN-enrolled women, including those receiving LNS, were given
2 kg/wk of maize flour for family consumption. From February to August
2005, there was a drought during which the World Food Programme
(WFP) provided food aid to HIV-infected women in Lilongwe. The WFP
ration, which included a similar quantity of corn/soy flour as the BAN
maize supplement plus 1 L of vitamin A-fortified corn oil per month, was
provided in lieu of the maize supplied by the study to ~260 BANmothers
during at least part of their study participation. The mothers who
received the WFP ration were evenly distributed across study arms.
All women were intensively counseled to exclusively breastfeed their
infants until 24 wk of age and to wean rapidly by 28 wk (33). Although it
is possible that there are delayed effects of maternal supplementation on
infant growth, only data up to 24 wk are included in the present analysis,
TABLE 1 Composition of the daily ration of LNS given to BAN











Niacin, mg equivalent 20
Pyridoxine, mg 2.2
Cyanocobalamine, mg 2.6
Ascorbic acid, mg 100
a-Tocopherol, mg 12






1 LNS contained ground peanuts, dried skimmed milk, vegetable fat, sugar, and a
multivitamin-mineral premix. BAN, Breastfeeding, Antiretrovirals, and Nutrition; LNS,
lipid-based nutrient supplement.
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because the infants began receiving LNS for their own consumption at
that time.
Mothers who had.5%weight loss between study visits or BMI,17
kg/m2 but who were not assigned to one of the maternal supplement
arms were given the same type and dose of LNS as mothers in the
supplement arms until their weight stabilized. Of the 25 mothers who
received LNS due to excess weight loss, 13 were in the mARV arm, 8
were in the iARV arm, and 4 were in the C arm. On average, they
consumed LNS for 6 (range 2–16) wk. On March 26, 2008, the data
safety monitoring board stopped enrollment in the no-ARV (mLNS and
C) arms, because HIV transmission through breast milk occurred more
frequently in these arms. Mothers in the mLNS and C arms were offered
the choice of remaining in the same arm or switching to either the
maternal or infant ARV interventions (34). Thirty-four mothers in our
analysis sample chose to switch arms: 30 to the maternal ARV and 4 to
the infant ARV arms. We conducted sensitivity analyses and found that
removing those infants whose mothers were given LNS to stabilize their
weight and those who switched frommLNS or C to one of the ARVarms
did not change our results. Consequently, these infants were retained in
their originally assigned study arms for the analysis.
Anthropometric measurements and other study procedures. All
study visits and data collection took place at the BAN study clinic at
Bwaila Hospital in Lilongwe, Malawi. Weight and recumbent length
were obtained from infants at the age of 0, 1, 2, 4, 6, 8, 12, 18, 21, and
24 wk using Tanita digital infant scales (0.1 kg increment) and wooden
length boards made to UNICEF specifications (0.1 cm increment) (35).
Scales were calibrated daily using a standard weight. Nurses and
nutrition assistants were trained to take anthropometric measurements
and their measurements were standardized (35).
Infant HIV status was tested using Amplicor 1.5 DNA PCR assay at
0, 2, 12, and 28 wk to identify infants who were infected postnatally
through breast milk. Positive HIV tests were confirmed with a new
specimen on the following visit. Dried blood spots, which were collected
at every study visit except 21 wk, were tested using Gen-Probe Aptima
HIV-1 Qualitative Assay to determine more precisely the timing of
infection in infants with positive PCR tests. A total of 58 infants in our
analysis sample became HIV infected between 2 and 24 wk.
Information on socio-economic characteristics was obtained from
mothers during screening. At 1, 4, 8, 12, and 21 wk, mothers who
received LNS reported how many full and half packets of the 2-packet
daily dose they consumed the day prior to the study visit. They also
stated how many of the packets they received on the last visit they had
remaining. Mothers assigned to LNS received it for 28 wk or until they
reported breastfeeding cessation, if this occurred first. Infants’ exclusive
breastfeeding status was assessed by maternal report at 4, 8, 12, 18, 21,
and 24 wk. Eighteen infants were fully weaned and 128 consumed a
mixed diet by 21 wk; most of these events occurred between 18 and
21 wk. An additional 71 infants became fully weaned and 126 became
mixed fed between 21 and 24 wk.
The BAN study initiated cotrimoxazole preventive therapy (CPT) for
infants 6–36 wk of age starting in June 2006, based on WHO recommen-
dations (36). Within our analysis sample, ~1500 infants received CPT.
Statistical analysis. The background characteristics of the 6 study arms
were compared to assess similarity using t tests for continuous, normally
distributed variables and chi-squared tests for categorical variables.
Nonparametric tests were conducted for skewed continuous variables.
Statistical analyses were carried out using Stata 11.2.
Longitudinal random effects models were used to analyze the effects
of study interventions on 3 outcomes: infant weight, length, and BMI.
The outcomes were modeled as having an exchangeable correlation
structure, which reflects our assumption that a participant’s measure-
ment at one visit is correlated with measurements at their other visits. All
analyses were stratified by sex due to significant differences in growth
patterns of boys and girls for all measures of growth. Based on a 2 3 3
factorial design (i.e., 2 levels for LNS supplementation and 3 levels for
ARV treatment), the initial analyses indicated a significant interaction
between the ARV and supplement interventions. Thus, in all subsequent
analyses, the 2 3 3 factorial design was collapsed into one factor
consisting of the 6 study arms. Because inclusion of maternal BMI,
education, and CD4+ count and infant CPT did not influence study arm
coefficients, they were excluded from the final longitudinal models,
which controlled for the corresponding birth measurement (e.g., birth
weight in the weight models) and treatment3 age and treatment3 age2
interactions, where appropriate. Likelihood ratio tests were used to
assess the joint significance of treatment 3 age and treatment 3 age2
interactions.
In a separate analysis, growth faltering was defined as .0.67-unit
decline in weight-for-age Z-score (WAZ) or length-for-age Z-score
TABLE 2 Background characteristics of 2121 mother-infant pairs in the BAN study, by study arm1
Characteristic mLNS-mARV mARV mLNS-iARV iARV mLNS C P value
n 377 374 391 381 299 299
Mothers
Age, y 25 (23–30) 26 (22–29) 26 (22–29) 25 (22–29) 26 (22–30) 26 (22–29) 0.97
Education beyond primary school, % 35.0 37.5 39.2 33.7 36.1 27.8 0.043
Married, % 94.4 89.3 94.1 91.9 91.0 93.0 0.08
First birth, % 10.6 12.5 13.0 12.9 11.2 10.4 0.81
BMI ,18.5,2 % 4.1 2.1 2.2 0.6 4.7 1.5 0.007
BMI .25,2 % 21.8 24.3 20.3 17.9 22.2 25.0 0.26
CD4+ count,3 cells/mm3 439 (328–582) 437 (329–565) 448 (324–611) 436 (337–559) 437 (326–578) 444 (337–574) 0.84
Infants
Male sex, % 49.6 49.7 50.6 49.3 50.2 53.2 0.95
Birth weight, kg 3.0 6 0.4 3.0 6 0.4 3.0 6 0.4 3.0 6 0.4 3.0 6 0.4 3.0 6 0.4 0.80
Low birth weight,4 % 5.8 8.8 6.1 6.8 6.7 5.7 0.57
Birth length, cm 48.3 6 2.0 48.2 6 2.0 48.1 6 1.9 48.3 6 1.9 48.3 6 2.1 48.0 6 1.9 0.46
Born during hungry season, % 30.2 30.2 30.7 29.7 36.5 35.1 0.27
CPT,5 % 80.1 79.2 78.3 79.2 72.7 73.1 0.16
1 Values are mean 6 SD, median (IQR), or percent. BAN, Breastfeeding, Antiretrovirals, and Nutrition; C, control; CPT, cotrimoxazole preventive therapy; iARV, infant antiretroviral
drug; mARV, maternal antiretroviral drug; mLNS, maternal lipid-based nutrient supplement; mLNS-iARV, maternal lipid-based nutrient supplement/infant antiretroviral drug; mLNS-
mARV, maternal lipid-based nutrient supplement/maternal antiretroviral drug.
2 BMI at 2 wk postpartum.
3 CD4+ during pregnancy.
4 Low birth weight defined as 2.0–2.5 kg, as infants were required to weigh $2.0 kg to be eligible for the study.
5 Proportion receiving CPT at 24 wk.
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(LAZ) from 0 to 24 wk. A 0.67-SD decrease in Z-score represents the
width of a percentile band on growth charts and is a clinically significant
event (37,38). The odds of faltering were estimated using logistic
regression, controlling for initial Z-scores.
Randomized infants were included in the longitudinal analysis
sample if they were singletons, did not become HIV infected or die
within the first 2 wk after birth, and had anthropometric measurements
on at least 2 of the 10 time points. Measurements for infants who became
HIV infected from 2 to 24 wk were included up to the point of infection
(determined by analysis of regularly collected dried blood spots).
Sensitivity analyses were conducted to examine the effect of removing
all measurements of infants who became HIV infected between 2 and
24 wk of age and measurements of infants after they were no longer
exclusively breastfed. We found that separate or simultaneous exclusion
of these groups of infants did not influence the results, so they were
retained in the models to maintain the intent of the clinical trial and limit
selection bias. Infants in the longitudinal analysis sample were included
in the faltering analysis if they had data at 0 and 24 wk. A small number
(,1%) of implausible post-birth weights and lengths were replaced by
values interpolated from prior and subsequent measures, assuming mean
growth rates observed in longitudinal regressionmodels of plausible values
stratified by sex.
Sample size and analysis sample. The method used to calculate
sample size for the main BAN study outcomes has been described
elsewhere (31). The present analysis had 80% power to detect a dif-
ference in mean weights of 200 g (~0.2 SD difference) between study
arms at 24 wk, when the sample was the smallest.
Of the 3572 HIV-1–infected pregnant women who underwent study
screening, 2791 delivered infants and 2369 mother-infant pairs were
randomized to the 6 study arms (Supplemental Fig. 1). Following the
exclusions described above, 2121 infants remained in the longitudinal
analysis sample for weight. The WAZ faltering analysis included 1661
infants who had data at 0 and 24 wk. Sample sizes for longitudinal
analyses of length (n = 2105) and BMI (n = 2103) as well as the analysis
of LAZ faltering (n = 1650) were slightly smaller than for weight and
WAZ due to missing length values. Among infants in the longitudinal
analysis sample for weight, 19% were not included in the faltering
analysis due to loss to follow-up and 1%due to death. These proportions
did not differ by study arm (loss to follow-up, P = 0.24; death, P = 0.69).
Three percent of the infants were not included in the faltering analysis,
because they became HIV infected between 2 and 24 wk of age. The
number of HIV-infected infants was larger in the no ARV arms (mLNS
and C), consistent with a previous report (8).
Results
Baseline characteristics of the mother-infant pairs included in the
longitudinal analysis were generally well balanced among the 6
study arms (Table 2), although the proportions with education
beyond primary school and low BMI (,18.5 kg/m2) were lower
in the C and iARV arms, respectively.
Based on adherence data collected at 5 study visits, 93.4% of
mothers reported consuming the full amount of LNS on the
previous day. The proportions were similar across LNS study
arms (mLNS, mLNS-mARV, and mLNS-iARV) and by infant
sex. The proportion of mothers who reported exclusive
breastfeeding at 21 wk was 96.5% and did not differ by study
arm or sex.
Mean infant weight, length, and BMI at each study visit are
reported in Supplemental Table 1. The longitudinal models
indicate that the average effect of the interventions on growth
was minimal, but there were some differences in effects over
time (Supplemental Table 2). Among infants whose mothers
received LNS, there were no differences in weight, length, or
BMI by ARV assignment (mLNS, mLNS-mARV, and mLNS-
iARV) (Fig. 1A). However, among infants whose mothers did
not receive LNS, boys in the C arm weighed more than boys in
either the iARVor mARVarms (Fig. 1B). Weights predicted from
the longitudinal model indicate that differences were largest
between the C and iARV arms, ranging from 130 g at 2 mo to
200 g at 5 mo of age. Based on the predicted means, boys in the
C arm also had higher BMI than boys in the iARVarm from 3 to
4 mo of age; the maximum difference was 0.4 kg/m2 at 4 mo. In
girls, there were differences between study arms over time in
weight and BMI, but not length. However, the differences were
smaller for girls than for boys and not clinically relevant.
From 0 to 24 wk, mean WAZ increased in all arms, whereas
mean LAZ remained static in girls and declined modestly in boys,
particularly in the C andmLNS arms (not shown). Approximately
21% of infants faltered in WAZ from 0 to 24 wk and LAZ
faltering occurred in 34% of infants. Overall, there was no
difference in the proportion of boys (21%) and girls (20%) whose
WAZ faltered (P = 0.51), but a larger proportion of boys (39%)
than girls (30%) faltered in LAZ (P , 0.001). The proportion of
infants faltering inweight and length from 0 to 24wk did not vary
by study arm for either sex (Table 3). Controlling for the
corresponding Z-score at birth, the odds ofWAZ or LAZ faltering
from 0 to 24 wk did not differ in any study arm compared with
the C arm (Table 3). In both sexes, the supplement did not
FIGURE 1 Boys’ predicted weight through age 6 mo in the mLNS,
mLNS-mARV, and mLNS-iARV arms of the longitudinal model (A) and
in the C, mARV, and iARV arms of the longitudinal model (B). C,
control; iARV, infant antiretroviral drug; mARV, maternal antiretroviral
drug; mLNS, maternal lipid-based nutrient supplement; mLNS-iARV,
maternal lipid-based nutrient supplement/infant antiretroviral drug;
mLNS-mARV, maternal lipid-based nutrient supplement/maternal
antiretroviral drug.
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influence WAZ or LAZ faltering within any ARV arm and ARV
was not associated with faltering within the supplement arms.
Discussion
The maternal nutritional supplementation component of the
BAN study was conducted with the expectation that at least
10% of HIV-infected mothers would have low BMI (,18.5 kg/
m2) (39) and many would have depleted energy or micronutrient
stores (21,40,41). The LNS were intended to improve or
maintain the mothers’ own nutritional status (42,43), which
could promote the growth of infants in these study arms. The
effect of ARV on the growth of HIV-exposed infants was
unknown and we did not have a priori hypotheses regarding
their influence on the outcomes. We found no consistent effects
of the maternal supplement across the 3 infant growth outcomes.
ARV, particularly infant nevirapine, had a negative effect on the
weight and BMI of boys as their age increased. As this effect was
not seen in boys whose mothers were nutritionally supple-
mented, LNS may have buffered an adverse effect of ARV on
growth. The differential effects of BAN study interventions on
boys and girls may be due to sex differences in the growth
process (44). During infancy, boys gain weight and length more
rapidly than girls (45), which could make boys more susceptible
to environmental insults, including the ingestion of ARV.
This research had some limitations. First, we cannot calculate
the net increase in maternal energy and nutrient intake attrib-
utable to LNS in the absence of dietary intake data. Second, it is
possible that our analysis of growth faltering from 0 to 24 wk
underestimates the actual prevalence of faltering in this popu-
lation due to the fairly sizeable number of participants who were
lost to follow-up by 24 wk. Infants who were lost to follow-up
were evenly distributed among the study arms.
The potential effects of maternal LNS supplementation on
infant growth may have been limited by the generally high BMI
of the BAN mothers. Compared with women of reproductive
age in Lilongwe (46), the BANmothers at 8 wk postpartumwere
less likely to have BMI,18.5 kg/m2 (3.4 vs. 6.0%, respectively)
and more likely to have BMI .25 kg/m2 (20.2 vs. 16.1%,
respectively). Thus, although BAN mothers were HIV infected,
they remained better nourished during lactation than the general
population of women of reproductive age in the same city. Other
research has shown that mothers and infants who were well
nourished had little if any benefit from maternal supplementa-
tion during pregnancy or lactation (23,24,47). Mothers in the
BAN study who received the LNS during lactation had less
weight loss than those who were not supplemented (30), in-
dicating that there were some mothers whose nutritional status
allowed them to benefit from the LNS.
The results of previous studies examining the effects of
maternal supplementation on infant growth have been mixed.
Three studies conducted in Columbia (24), Guatemala (25,26),
and Tanzania (27) provided maternal supplements during
pregnancy and lactation and found positive effects on infant
growth at different time points ranging from 6 to 24 mo of age,
whereas a study in Taiwan found no effect (28). It is notable that
the study in Guatemala found benefits on infant growth only in
supplemented mothers who were thinner (24). Two other studies
in Guatemala (23) and South Africa (29) supplemented mothers
during lactation only and reported positive effects for thinner
mothers themselves but found no impact on infant growth,
which is consistent with the results of the BAN study. The
Guatemala study showed that thinner, supplemented mothers
had higher breast milk energy content and output, indicating one
of the biological mechanisms through which maternal supple-
mentation could improve infant growth (23). The South African
study is most comparable to the one presented here, because the
supplement and study population were similar and high mean
maternal BMI likely limited the effect of maternal supplemen-
tation in both cases (29). Taken together, these results suggest
TABLE 3 Proportion of BAN infants whose WAZ and LAZ faltered by study arm and odds of growth
faltering from 0–24 wk compared to the control arm1
Boys Girls
% Who faltered2 OR3 95% CI P value % Who faltered OR 95% CI P value
WAZ faltering4 n = 855 n = 806
C (ref) 19.5 — — — 20.2 — — —
mLNS 24.8 1.25 (0.64, 2.42) 0.51 23.6 1.30 (0.65, 2.60) 0.46
mARV 23.7 1.25 (0.68, 2.31) 0.47 19.9 0.85 (0.44, 1.67) 0.64
mLNS-mARV 19.2 0.97 (0.52, 1.82) 0.93 20.4 1.00 (0.52, 1.93) 0.99
iARV 22.1 1.09 (0.59, 2.02) 0.79 20.5 0.99 (0.52, 1.88) 0.97
mLNS-iARV 19.9 1.16 (0.62, 2.16) 0.64 17.2 0.75 (0.39, 1.45) 0.39
LAZ faltering5 n = 846 n = 804
C (ref) 30.3 — — — 28.7 — — —
mLNS 44.8 1.68 (0.94, 3.03) 0.08 20.8 0.59 (0.30, 1.14) 0.11
mARV 40.9 1.71 (0.99, 2.95) 0.06 26.7 0.76 (0.42, 1.39) 0.37
mLNS-mARV 41.0 1.64 (0.95, 2.83) 0.08 30.1 0.92 (0.51, 1.63) 0.76
iARV 38.2 1.44 (0.83, 2.50) 0.19 32.1 1.01 (0.58, 1.78) 0.97
mLNS-iARV 36.9 1.48 (0.86, 2.56) 0.16 36.3 1.35 (0.77, 2.35) 0.28
1 Faltering is .0.67 decline in Z-score. BAN, Breastfeeding, Antiretrovirals, and Nutrition; C, control; iARV, infant antiretroviral drug; LAZ,
length-for-age Z-score; mARV, maternal antiretroviral drug; mLNS, maternal lipid-based nutrient supplement; mLNS-iARV, maternal lipid-
based nutrient supplement/infant antiretroviral drug; mLNS-mARV, maternal lipid-based nutrient supplement/maternal antiretroviral drug;
WAZ, weight-for-age Z-score.
2 Proportion of infants who faltered from 0 to 24 wk of age.
3 Estimated OR of faltering with C as the reference group (ref) based on logistic regression.
4 The models were adjusted for WAZ at birth.
5 The models were adjusted for LAZ at birth.
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that maternal supplementation should be targeted at women
with poor nutritional status, even in HIV-infected populations.
Because we found no large differences in infant growth
between the study arms, it is useful to put our findings into
context. Infants in previous studies of HIV-exposed, uninfected
children usually had a short period of exclusive breastfeeding
followed by mixed feeding, which contributed to similar
patterns of growth faltering in HIV-exposed and unexposed
children (48). Compared with 2 other groups of Malawian
infants in Lungwena with short periods of exclusive breastfeed-
ing and ,20% prevalence of HIV among mothers, on average,
the BAN infants were approximately the same weight but ;1–3
cm longer at 6 mo of age (49,50). Possible explanations for the
somewhat better linear growth of BAN infants are residence in
an urban area compared with the rural Lungwena cohorts and
the extensive counseling and support for exclusive breastfeeding
provided by the BAN study nurses (33), which was not available
in Lungwena.
In conclusion, the growth of infants whose mothers received
LNS did not differ from infants whose mothers did not receive
LNS during the period of exclusive breastfeeding. Boys who
were not exposed to ARV had slightly better weight and BMI
with increasing age than those with ARV exposure. These
differences were small and unlikely to have clinical importance.
Although the study interventions had little effect on growth
compared with the controls, the BAN HIV-exposed infants had
somewhat better linear growth than other Malawian infants.
This suggests that good counseling on exclusive breastfeeding
may be beneficial to the growth of HIV-exposed infants.
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